The Federal Antimonopoly Service (FAS) of Russia has approved the prices for the first domestic generic version of the diabetes drug Stiglatra.
Ertugliflozin, developed by the Russian company Life Sciences OCPC for treating adults with inadequately controlled type 2 diabetes, will be priced 12.8% lower than the original branded drug.
The Federal Antimonopoly Service (FAS) announced that the price for a package of 28 tablets (5 mg dosage) of the generic has been set at 2,083 rubles. For comparison, the minimum price for an equivalent pack of the original medication in reference countries is 2,388 rubles.
According to Russia’s State Register of Medicines (GRLS), the ertugliflozin tablets are produced at the Obninsk Chemical and Pharmaceutical Company (OCPC) plant in the Kaluga region, using the active pharmaceutical ingredient supplied by the Indian firm Azico Biophore.
The original drug, Stiglatra by the American pharmaceutical giant MSD, was delisted from the GRLS in October 2023.
Ertugliflozin is an oral hypoglycemic agent that works by blocking the SGLT2 protein, responsible for reabsorbing glucose from the kidneys into the bloodstream. By inhibiting this process, the drug promotes the excretion of excess glucose through urine, aiding in diabetes management. It is indicated both as monotherapy (for patients who cannot take the standard first-line treatment, metformin) and as part of combination therapy (together with other glucose-lowering agents such as metformin, insulin, or sulfonylureas) when blood sugar levels remain inadequately controlled.
